Phase I-b study of isatuximab plus carfilzomib in relapsed and refractory multiple myeloma (RRMM).

被引：4
|
作者：
Chari, Ajai
Richter, Joshua Ryan
Shah, Nina
Wong, Sandy Wai Kuan
Jagannath, Sundar
Cho, Hearn J.
Biran, Noa
Wolf, Jeffrey
Parekh, Samir S.
Munster, Pamela N.
Madduri, Deepu
Campana, Frank
Martin, Thomas G.
机构：
[1] Mt Sinai, Icahn Sch Med, Tisch Canc Inst, New York, NY USA
[2] Hackensack Univ, John Theurer Canc Ctr, Med Ctr, Hackensack, NJ USA
[3] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[4] Tufts, San Francisco, CA USA
[5] Mt Sinai Hosp, New York, NY 10029 USA
[6] Mt Sinai, Hematol & Med Oncol, Icahn Sch Med, New York, NY USA
[7] UCSF Med Ctr, San Francisco, CA USA
[8] Albert Einstein Coll Med, Bronx, NY 10467 USA
[9] Univ Calif San Francisco, San Francisco, CA 94143 USA
[10] Mt Sinai Med Ctr, New York, NY 10029 USA
[11] Sanofi US, Cambridge, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.8014
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8014
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Phase III (IKEMA) study design: Isatuximab plus carfilzomib and dexamethasone (Kd) vs Kd in patients with relapsed/refractory multiple myeloma (RRMM).
    Martin, Thomas G.
    Dimopoulos, Meletios A.
    Yong, Kwee
    Mikhael, Joseph
    Risse, Marie-Laure
    Asset, Gaelle
    Moreau, Philippe
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [2] A PHASE IB STUDY OF ISATUXIMAB PLUS POMALIDOMIDE (POM) AND DEXAMETHASONE (DEX) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
    Mikhael, J.
    Richardson, P.
    Usmani, S.
    Raje, N.
    Bensinger, W.
    Kanagavel, D.
    Gao, L.
    Ziti-ljajic, S.
    Anderson, K.
    HAEMATOLOGICA, 2017, 102 : 168 - 168
  • [3] Isatuximab plus carfilzomib/dexamethasone versus carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma: IKEMA Phase III study design
    Moreau, Philippe
    Dimopoulos, Meletios A.
    Yong, Kwee
    Mikhael, Joseph
    Risse, Marie-Laure
    Asset, Gaelle
    Martin, Thomas
    FUTURE ONCOLOGY, 2020, 16 (02) : 4347 - 4358
  • [4] A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma
    Mikhael, Joseph
    Richardson, Paul
    Usmani, Saad Z.
    Raje, Noopur
    Bensinger, William
    Karanes, Chatchada
    Campana, Frank
    Kanagavel, Dheepak
    Dubin, Franck
    Liu, Qianying
    Semiond, Dorothee
    Anderson, Kenneth
    BLOOD, 2019, 134 (02) : 123 - 133
  • [5] A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma
    Martin, Thomas
    Baz, Rachid
    Benson, Don M.
    Lendvai, Nikoletta
    Wolf, Jeffrey
    Munster, Pamela
    Lesokhin, Alexander M.
    Wack, Claudine
    Charpentier, Eric
    Campana, Frank
    Vij, Ravi
    BLOOD, 2017, 129 (25) : 3294 - 3303
  • [6] Phase Ib Study of Isatuximab and Carfilzomib in Relapse and Refractory Multiple Myeloma
    Martin, Thomas G., III
    Mannis, Gabriel N.
    Chari, Ajai
    Munster, Pamela
    Campana, Frank
    Hui, Ai-Min
    Wolf, Jeffrey L.
    BLOOD, 2016, 128 (22)
  • [7] A Phase 1b/2 Study of Selinexor, Carfilzomib, and Dexamethasone (SKd) in Relapsed/ Refractory Multiple Myeloma (RRMM)
    Gasparetto, Cristina
    Schiller, Gary J.
    Callander, Natalie Scott
    Lentzsch, Suzanne
    Tuchman, Sascha A.
    Bahlis, Nizar
    White, Darrell J.
    Chen, Christine I.
    Sutherland, Heather J.
    Baljevic, Muhamed
    Kotb, Rami
    Leblanc, Richard
    Sebag, Michael
    Venner, Christopher P.
    Bensinger, William I.
    Sheehan, Heidi
    Chai, Yi
    Kai, Kazuharu
    Shah, Jatin
    Shacham, Sharon
    Kauffman, Michael G.
    Lipe, Brea C.
    BLOOD, 2019, 134
  • [8] Updated Results from a Phase Ib Study of Isatuximab Plus Pomalidomide (Pom) and Dexamethasone (dex) in Relapsed/Refractory Multiple Myeloma (RRMM)
    Richardson, Paul G.
    Mikhael, Joseph
    Usmani, Saad Z.
    Raje, Noopur
    Bensinger, William
    Kanagavel, Dheepak
    Gao, Lei
    Ziti-Ljajic, Samira
    Anderson, Kenneth C.
    BLOOD, 2017, 130
  • [9] Final results of a phase Ib study of isatuximab (ISA) plus pomalidomide (Pom) and dexamethasone (dex) in relapsed/refractory multiple myeloma (RRMM).
    Mikhael, Joseph
    Richardson, Paul G.
    Usmani, Saad Zafar
    Raje, Noopur S.
    Bensinger, William
    Dubin, Franck
    Liu, Qianying
    Vitse, Olivier
    Anderson, Kenneth Carl
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [10] Final Analysis of a Phase 1b Study of Daratumumab in Combination with Carfilzomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma (RRMM)
    Chari, Ajai
    Lonial, Sagar
    Martinez-Lopez, Joaquin
    Mateos, Maria-Victoria
    Blade, Joan
    Benboubker, Lotfi
    Oriol, Albert
    Otero, Paula Rodriguez
    Pineiro, Luis
    Jakubowiak, Andrzej
    Olyslager, Yunsi
    Wang, Jianping
    Nnane, Ivo
    Ukropec, Jon
    Shreeve, Martin
    Qi, Ming
    Moreau, Philippe
    BLOOD, 2019, 134
12345